Psychopharmacotherapy in children and adults with intellectual disability (Q33696362)

28 July 2017

1 reference

title

Psychopharmacotherapy in children and adults with intellectual disability (English)

1 reference

28 July 2017

0 references

intellectual disability

1 reference

disability affecting intellectual abilities

inferred from title

1 reference

P J Santosh

1

1 reference

28 July 2017

G Baird

series ordinal

2

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 July 1999

1 reference

28 July 2017

1 reference

28 July 2017

volume

354

1 reference

28 July 2017

issue

9174

1 reference

28 July 2017

page(s)

233-242

1 reference

Validity of the PAS-ADD for detecting psychiatric symptoms in adults with learning disability (mental retardation).

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Use of psychotropic medication in Oklahoma: a statewide survey.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

The use of anti‐psychotic drugs with adults with learning disabilities and challenging behaviour

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

The international consensus process on psychopharmacology and intellectual disability

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Child and learning disability psychopharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

A double-blind comparison of zuclopenthixol tablets with placebo in the treatment of mentally handicapped in-patients with associated behavioural disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Effectiveness of zuclopenthixol compared with haloperidol in the treatment of behavioural disturbances in learning disabled patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Risperidone as add-on therapy in behavioural disturbances in mental retardation: a double-blind placebo-controlled cross-over study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Efficacy and specificity of pharmacological therapies for behavioral disorders in persons with mental retardation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Fluoxetine Treatment of Children and Adults with Autistic Disorder and Mental Retardation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Effects of fluoxetine on aggressive behavior of adult inpatients with mental retardation and epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Paroxetine treatment of aggression and self-injury in persons with mental retardation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Clomipramine treatment of stereotypic behaviors and self-injury in patients with developmental disabilities

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Clinical effects of buspirone on intractable self-injury in adults with mental retardation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

The effect of buspirone on challenging behaviour in mentally retarded patients: an open prospective multiple-case study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults. Double-blind placebo-controlled studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Changes in naloxone and haloperidol effects during the development of captivity-induced jumping stereotypy in bank voles

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Lithium in the treatment of aggression in mentally handicapped patients. A double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Factors associated with a good response to lithium in aggressive mentally handicapped subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Lithium in Non-Manic-Depressives: Antiaggressive Effect and Red Blood Cell Lithium Values

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Antilibidinal drugs and mental retardation: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Use of melatonin in the treatment of paediatric sleep disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Psychiatric disorders in children and adolescents with mental retardation and active epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Effects of tryptophan depletion in drug-free adults with autistic disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Risperidone and explosive aggressive autism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

An open trial of risperidone in young autistic children.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Use of methylphenidate in the treatment of children with autistic disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Effects of fluoxetine treatment in young children with idiopathic autism.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Clinical effect of buspirone in autistic children.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: results of an open-label study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Clonidine treatment of hyperactive and impulsive children with autistic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Naltrexone in autistic children: behavioral symptoms and attentional learning

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Naltrexone in young autistic children: a double-blind, placebo-controlled crossover study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Placebo-controlled acute dosage naltrexone study in young autistic children.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

The adrenocorticotrophic hormone (4-9) analog ORG 2766 benefits autistic children: report on a second controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

A controlled trial with ORG 2766, an ACTH-(4-9) analog, in 50 relatively able children with autism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Effects and noneffects of methylphenidate in children with mental retardation and ADHD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Fenfluramine and methylphenidate in children with mental retardation and ADHD: clinical and side effects.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Prediction of response to methylphenidate among children with ADHD and mental retardation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Long-term follow-up of children with mental retardation/borderline intellectual functioning and ADHD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

The use of clozapine in borderline-intellectual-functioning and mentally retarded schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Prader-Willi syndrome and cycloid psychoses.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Prader-Willi syndrome and psychoses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Neuropsychiatric aspects of adult-onset Tay-Sachs disease: two case reports with several new findings

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

Psychiatric disorders in 36 families with Wolfram syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907059-7

7 January 2021

10.1016/S0140-6736(98)07059-7

Identifiers

DOI

1 reference

28 July 2017

1 reference